| Date | Title | | | 09/08/10 | Idera Pharmaceuticals to Present at Upcoming Investor Conferences| CAMBRIDGE, Mass., Sep 08, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its drug discovery and development programs targeted to Toll-like Receptors and a general corporate update at the following conferences:
The Rodman & Renshaw Annual Global Investment Conference on Wednesday, September 15 at 10:50 a.m. ET at the New York Palace Hotel, New York City
The UBS Global Life Sciences Conference on Monday, September 20 ... |
|  | | 08/27/10 | Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment| - Clinical Trial Initiated in First-Line Treatment of Patients with Head and Neck Cancer -
CAMBRIDGE, Mass., Aug 27, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combinatio... |
| | | 08/05/10 | Idera Pharmaceuticals Reports Second Quarter 2010 Financial Results and Provides Pipeline Update| CAMBRIDGE, Mass., Aug 05, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLRs), today reported financial results for the second quarter ended June 30, 2010.
"We are progressing the clinical development programs of IMO-2125, our lead candidate for chronic hepatitis C virus infection, and IMO-3100, our lead candidate for autoimmune and infla... |
| | | 08/02/10 | Idera Pharmaceuticals to Raise $15 Million in Registered Direct Offering| CAMBRIDGE, Mass., Aug 02, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals (Nasdaq: IDRA) today announced that it has received commitments from certain institutional investors to purchase approximately $15 million of securities in a registered direct offering. Idera expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.
In the offering Idera has agreed to sell approximately 4.0 million units, each unit consisting of one sha... |
| | | 07/08/10 | Idera Pharmaceuticals Announces Issuance of New Patents for Its Toll-like Receptor-Targeted Compounds| CAMBRIDGE, Mass., Jul 08, 2010 (BUSINESS WIRE) --
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs). The Company's intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain o... |
| | | 06/21/10 | Idera Pharmaceuticals Announces the Election of Eve E. Slater, M.D.,
F.A.C.C., to Its Board of Directors| CAMBRIDGE, Mass., Jun 21, 2010 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the election
of Eve E. Slater, M.D., F.A.C.C., to the Company's Board of Directors as
a class III director. Dr. Slater is board certified in internal medicine
and cardiology and has extensive experience in the pharmaceutical
industry, most recently serving as senior vice president for worldwide
policy at Pfizer, Inc. Prior to joining Pfizer, she serv... |
| | | 06/08/10 | Idera Pharmaceuticals Announces Preliminary Data from Phase 1
Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Drug
Candidate for Autoimmune and Inflammatory Diseases| CAMBRIDGE, Mass., Jun 08, 2010 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced preliminary
results from a Phase 1 clinical trial of IMO-3100, its lead Toll-like
Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential
applications in autoimmune and inflammatory diseases. In this trial,
healthy subjects in five dosage cohorts received single doses of
IMO-3100 from 0.04 to 0.64 mg/kg. IMO-3100 was well tolerated at all
... |
| | | 06/04/10 | Idera Pharmaceuticals Announces Publication of Preclinical Data on
Cancer Immunotherapy with its Dual Agonist of Toll-like Receptors 7 and 8| CAMBRIDGE, Mass., Jun 04, 2010 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the
publication of data from studies of a dual agonist of Toll-like Receptor
7 (TLR7) and TLR8 in preclinical models of cancer. The Company created
this first-in-class RNA-based dual agonist of TLR7 and TLR8 through its
chemistry-based approach to identifying novel TLR-targeted drug
candidates. The paper entitled "Antitumor Activity and Immune Respon... |
| | | 05/28/10 | Idera Pharmaceuticals to Present at Upcoming Investor Conferences| CAMBRIDGE, Mass., May 28, 2010 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will
provide an overview of its Toll-like Receptor-targeted drug discovery
and development programs and a general corporate update at the following
conferences:
The Sixth Annual Noble Financial Capital Market's Equity Conference on
Tuesday, June 8 at 2:00 p.m. EDT at The Hard Rock Hotel in Hollywood,
FL.
... |
| | | 05/12/10 | Idera Pharmaceuticals to Present at Rodman & Renshaw 6th
Annual Global Healthcare Conference| CAMBRIDGE, Mass., May 12, 2010 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will
provide an overview of its Toll-like Receptor-targeted drug discovery
and development programs and a general corporate update at the Rodman
& Renshaw 6th Annual Global Healthcare Conference on Monday, May
17, at 12:20 p.m. BST (7:20 a.m. EDT) being held at the Grosvenor House
Hotel in London, UK.
The presentation will be availabl... |
| | | 05/04/10 | Idera Pharmaceuticals Reports First Quarter 2010 Financial Results
and Provides Pipeline Update| CAMBRIDGE, Mass., May 04, 2010 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today reported
financial results for the first quarter ended March 31, 2010.
"We are very encouraged by the interim clinical data with IMO-2125, a
TLR9 agonist, in the difficult-to-treat null responder HCV patients. The
da... |
| | | 04/15/10 | Idera Pharmaceuticals Announces Positive Phase 1 Data of IMO-2125 in
Null Responder HCV Patients at EASL 2010| - IMO-2125 Shown to Induce Interferon-alpha and Other Cytokines -
- Interferon-alpha Induction Correlates with Viral Load Reductions -
CAMBRIDGE, Mass., Apr 15, 2010 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced today that positive
interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like
Receptor 9 (TLR9) agonist, in null responder patients with chronic
hepatitis C virus (HCV) infection were presented at the 45th
Annual Meet... |
| | | 04/08/10 | Idera Pharmaceuticals Presents Data on Anti-Atherogenic Effects of
Toll-like Receptor Antagonist in Preclinical Model of Atherosclerosis at
American Heart Association Conference| CAMBRIDGE, Mass., Apr 08, 2010 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presented data from a
preclinical study evaluating the mechanism of action of a Toll-like
Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The
presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti
atherogenic effects in ApoE-/- mouse model of
atherosclerosis" (abstract P259) was made by Idera scientists at the
Ameri... |
| | | 04/07/10 | Idera Pharmaceuticals Announces Management Appointments and Promotion| CAMBRIDGE, Mass., Apr 07, 2010 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the
appointments of Robert Arbeit, M.D., as Vice President of Clinical
Development, and Nicola La Monica, Ph.D., as Vice President of Biology,
and the promotion of Timothy Sullivan, Ph.D., the Company's Vice
President of Development Programs, to Vice President of Development
Programs and Alliance Management.
"We are very pleased to have Bob and Ni... |
| | | 03/17/10 | Idera Pharmaceuticals Announces Acceptance of IMO-2125 Abstracts for
Presentation at EASL Annual Meeting| CAMBRIDGE, Mass., Mar 17, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that two
abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125,
were accepted for presentation at the 45th Annual Meeting of
the European Association for the Study of the Liver (EASL) in Vienna,
Austria, April 14-18, 2010. IMO-2125 is being evaluated for potential
applications in chronic hepatitis C virus (HCV) infection. The accept... |
| | | 03/12/10 | Idera Pharmaceuticals to Present an Overview of Toll-like Receptor
Antagonist Program at 8th World Congress on
Trauma, Shock, Inflammation and Sepsis| CAMBRIDGE, Mass., Mar 12, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), announced that Sudhir
Agrawal, D. Phil., Chief Executive Officer and Chief Scientific Officer,
will present today an overview of TLR antagonists and their applications
in autoimmune and inflammatory diseases in a talk entitl... |
| | | 03/10/10 | Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2009
Financial Results| CAMBRIDGE, Mass., Mar 10, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial
results for the fourth quarter and full year ended December 31, 2009.
"We met our 2009 key objectives of advancing our Toll-like
Receptor-targeted drug candidates and expanding our pipeline with the
addition of IMO-3100, a TLR antagonist for potential application in
autoimmune diseases," said Sudhir Agrawal, D.Phil., Chief Executive
Office... |
| | | 03/09/10 | Idera Pharmaceuticals to Present at Roth 22nd
Annual Orange County Growth Stock Conference| CAMBRIDGE, Mass., Mar 09, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will discuss its drug discovery and development programs and provide
a general corporate overview at the Roth 22nd Annual Orange
County Growth Stock Conference on Wednesday, March 17, at 1:30 p.m. PST... |
| | | 03/03/10 | Idera Pharmaceuticals to Present at Cowen and Company 30th
Annual Health Care Conference| CAMBRIDGE, Mass., Mar 03, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will discuss its drug discovery and development programs and provide
a general corporate overview at the Cowen and Company 30th Annual Health
Care Conference on Tuesday, March 9, at 3:00 p.m. EST at t... |
| | | 02/23/10 | Idera Pharmaceuticals Presents Mechanism of Action Data on IMO-3100,
a Novel Toll-like Receptor Antagonist for Autoimmune Diseases, at
Keystone Symposium| CAMBRIDGE, Mass., Feb 23, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presented data on the
mechanism of action of IMO-3100, an antagonist of Toll-like Receptor
(TLR) 7 and TLR9, in a preclinical primate model at the Keystone
Symposia conference "Tolerance and Autoimmunity" being held February
21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the
treatment of autoimmune diseases. The presentation entitled "IMO-3100, a... |
| | | 02/14/10 | Idera Pharmaceuticals Presents Preclinical Hyperlipidemia Data on a
Toll-like Receptor Antagonist at Keystone Symposium| CAMBRIDGE, Mass., Feb 14, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) presented data on the
evaluation of a Toll-like receptor (TLR) antagonist in a preclinical
hyperlipidemia model today at the Keystone Symposia conference "Advances
in Molecular Mechanisms of Atherosclerosis" being held in Banff,
Alberta, Canada. Idera's proprietary TLR antagonists have dual activity
for both TLR7 and TLR9, and present a potentially innovative appro... |
| | | 02/02/10 | Idera Pharmaceuticals to Present at Annual BIO CEO & Investor Conference 2010| Cambridge, MA, February 2, 2010 – Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its drug discovery and development programs and provide a general corporate overview at the 12h Annual BIO CEO & Investor Conference on Monday, February 8, at 11:00 a.m. EST at the Waldorf Astoria Hotel in New York.
The pres... |
| | | 01/28/10 | Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a
Toll-like Receptor Antagonist Intended for Autoimmune Disease Indications| CAMBRIDGE, Mass., Jan 28, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced initiation of
a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like
Receptor (TLR) 7 and TLR9.
"As an antagonist of TLR7 and TLR9, IMO-3100 has a novel mechanism of
action and presents a potentially innovative approach in the treatment
of a number of autoimmune diseases," said Sudhir Agrawal, D.Phil., Chief
Executive Officer and Chief Sc... |
| | | 01/26/10 | Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss,
Ph.D., to Its Board of Directors| CAMBRIDGE, Mass., Jan 26, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the election
of Malcolm MacCoss, Ph.D., FRSC, to the Company's Board of Directors as
a class II director. Dr. MacCoss has nearly 30 years of drug discovery
and development experience with large international pharmaceutical
companies.
"Dr. MacCoss' extensive accomplishments include critical contributions
to bringing many important drugs to market," ... |
| | | 01/19/10 | Idera Pharmaceuticals Announces Achievement of Clinical Milestone
Under Its Collaboration with Merck KGaA for Cancer Treatment| - Merck KGaA Initiates Phase 2 Clinical Trial in Patients with Head and Neck Cancer -CAMBRIDGE, Mass., Jan 19, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has
achieved a milestone under its worldwide licensing and collaboration
agreement with Merck KGaA, Darmstadt, Germany. The milestone was
achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD
1201081, a novel agonist of Toll-like Receptor 9 (TLR9), in co... |
| |
|
